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Since its conception in 1940 the American Diabetes Associa-
tion (ADA) has been chairing an annual conference, which has
become one of the key international forums for sharing knowl-
edge and disseminating new research into Diabetes mellitus. June
2016 saw the ADA’s 76th Scientiﬁc Sessions, this year held in New
Orleans, USA. More than 15,000 clinicians, health care profession-
als and scientists involved in diabetes care and research joined
together for a ﬁve day program. We were fortunate to be spon-
sored to attend by Elsevier.
The conference consisted of eight parallel themes, covering acute
and chronic complications, behavioural medicine, clinical nutri-
tion, education and exercise, clinical diabetes and therapeutics,
epidemiology and genetics, insulin action and molecular metabo-
lism, and integrated physiology and obesity.
Exciting new data emerging from clinical trials
Two of the highlights of this year’s scientiﬁc sessions were the
presentation of the latest results of two major clinical trials, the
Liraglutide Effect and Action in Diabetes – Evaluation of Cardiovas-
cular Outcome Results (LEADER) Trial and the EMPA-REG Outcome
Trial.
The LEADER trial randomised more than 9000 individuals with
type 2 diabetes to GLP-1 agonist Liraglutide or placebo, on top of
standard care. Study participants had either had a prior cardiovas-
cular event or were at high risk of future cardiovascular events. In
this much anticipated session the investigators reported their ﬁnd-
ings after between 3.5 and 5 years of follow up. There was a
signiﬁcant 22% reduction in cardiovascular death and a 15% in all-
cause mortality, with non-signiﬁcant reductions in non-fatal
myocardial infarction and stroke. The investigators also reported
signiﬁcant reductions on HbA1c, weight and risk of severe
hypoglycaemia with Liraglutide. This trial was the ﬁrst to show a
cardiovascular beneﬁt of a GLP-1 inhibitor.
The conference also saw the awaited update on the EMPA-REG
outcome trial. To date Empagliﬂozin is the only other diabetes drug
of any class to show a cardiovascular beneﬁt. The EMPA-REG outcome
trial recruited more than 7000 individuals with type 2 diabetes and
at high cardiovascular risk and randomised them to either the SGLT2
inhibitor Empagliﬂozin or placebo. Empagliﬂozin demonstrated a
38% reduction in cardiovascular death, a 32% reduction in all-
cause mortality and a 35% reduction in hospitalisation for heart
failure, effects that were consistent across age groups and LDL-
cholesterol subgroups. New data reported showed that Empagliﬂozin
also signiﬁcantly decreased the progression of nephropathy by 39%,
with an associated reduction in new onset macroalbuminuria. The
mechanisms underlying the observed cardiovascular and renal ben-
eﬁts are uncertain but appear to go beyond its effects on glycaemic
control. Together the presentation of these trial results sparkedmuch
debate about the possibility of using diabetic therapies for ben-
eﬁts beyond their glycaemic effects.
Advances in diabetes disease modelling: genome-edited
human stem cells
Another of the biggest talking points of themeeting was the com-
plimentary use of human stem cells and genome-editing
technologies for diabetes disease modelling. Dieter Egli (Columbia
UniversityMedical Center, USA) kicked off the ‘Update on Cell Sources
for Beta-Cell Replacement’ session by setting the scene for stem cells
as a source of human endocrine pancreas-like tissue, discussing the
pros and cons of obtaining such cells via in vitro-directed differen-
tiation and in vivo-maturation protocols. After approximately one
month of differentiation-in-a-dish, Egli’s teamwere able to produce
endocrine pancreas-like cells capable of insulin secretion in
response to a variety of secretagogues. However, by far and away
the most impressive functional data were that obtained from cells
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matured in SCID mice. Egli showed that near 100% of in vivo-
derived cells were positive for c-peptide (up from 50% of in vitro
cells), and demonstrated glucose-responsive insulin secretion when
tested ex vivo, and in STZ-diabetic mice. Glycaemia was even re-
stored when the transplanted stem cell-derived pancreatic
progenitors were obtained from donors with type 1 diabetes (T1D).
This, teamed with Egli’s successful correction of stem cells from in-
dividuals with HNF1A and ABCC8 mutations using the site-speciﬁc
nuclease CRISPR-Cas9 system, suggests that in addition to disease
modelling, the eventual use of such cells for autologous transplan-
tation is theoretically possible.
Rohit Kulkarni (Joslin Diabetes Center, USA) also presented data
whereby induced pluripotent stem cells (iPSCs) derived from T1D
‘medallists’ (individuals with T1D for 50 years or over) were used
to understand themechanisms underlying diabetes-associated com-
plications. Kulkarni and colleagues showed a major role for DNA
damage repair genes, as well as inﬂammatory pathways, highlight-
ing the utility of patient-derived stem cells in modelling all aspects
of diabetes dysfunction and comorbidities.
Whilst much of our understanding of endocrine pancreas de-
velopment has been gleaned from rodent studies, the overlap with
human islet generation is not complete. Paul Gadue (University of
Pennsylvania, USA) demonstrated the utility of stem cell-derived
islet-like cells in modelling human development, by using cells from
individuals harbouring pancreatic agenesis-causing GATA6 muta-
tions to show that this transcription factor transmits pro-survival
signals following primitive streak induction. Additionally, and by
far and away the biggest achievement of Gadue’s teamwas the gen-
eration of ‘endodermal progenitor stem cell lines’ – sorted deﬁnitive
endoderm cells cultured in a cocktail of signalling factors – which
can be bulked up, banked, and revived for use in disease model-
ling. This not only abolishes the need for per-experiment deﬁnitive
endoderm induction and the heterogeneity this brings, but also
facilitates disease modelling where mutations (like those
in GATA6) reducing viability of endodermal- and early islet-
developmental cell types, can be studied.
This work was complemented by that of Danwei Huangfu (Me-
morial Sloan Kettering Center, USA) who presented data on her
innovative inducible CRISPR-Cas9 system. Upregulation of this site-
speciﬁc nuclease from the safe-harbour AAVS1 locus in human stem
cells was used to generate both hetero- and homozygous GATA4 and
GATA6 knockout lines, as well as introduce novel GATA6 mutations.
Huangfu’s team showed that dysfunctional GATA6 leads to altered
levels of key pancreatic transcription factors including PDX1 and
NKX6.1. Reduction in these transcription factors correlated with
reduced islet-like function, conﬁrming their importance in endo-
crine pancreas cell maturation.
Moving on from disease modelling: ‘naked stem cells’ could be
transplanted into any individual with diabetes
Looking to the future and moving on from the ‘simple’ use of
stem cell-derived islet-like cells in disease modelling, as an alter-
native source of endocrine pancreas tissue, it is theoretically very
possible that these cells could be transplanted into individuals with
diabetes. However, for any stem cell-derived cells to be of use in
diabetes treatment, their tolerance by and/or protection from an in-
dividual’s immune systemmust be addressed. Whilst several in the
ﬁeld continue to investigate the use of artiﬁcial encapsulation devices
in the clinic, Chad Cowan (Harvard Stem Cell Institute, USA) pre-
sented an innovative take on this issue; using CRISPR-Cas9 to
generate universal donor stem cells. Such ‘naked stem cells’ would
be analogous to O Rhd negative blood, which with the absence of
antigens, could be given to any donor. By targeting the major his-
tocompatibility complex genes alongside those encoding master
regulators of antigen presentation, it was hoped that these cells
would not be rejected upon transplantation into mice with
humanised immune systems. However, their quick rejection and de-
struction suggests that they are still recognisable to a subset of
memory T-cells within these rodents. Accordingly, Cowan’s team
continue with a two-pronged attack on transplantation of islet-
like cells, working to ‘induce immune tolerance’ in the cell recipient
alongside reducing the immunogenicity of transplanted cells.
The future of diabetes research and clinical care looks bright
This year’s scientiﬁc sessions saw a high standard of both clin-
ical and basic science research, and provided a forum for lively
discussion from clinicians and scientists from across the globe. We
are in an exciting era for diabetes, with the presented advances in
biological understanding gleaned from clinical trials alongside state-
of-the-art human physiologically-relevant disease models, the sense
from this year’s scientiﬁc sessions was that diabetes research and
care is moving forward at a timely pace.
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